Fluctuations in haemoglobin levels in haemodialysis, pre-dialysis and peritoneal dialysis patients receiving epoetin alpha or darbepoetin alpha: Original Article

Nephrology

Volumn 14, Issue 7, 2009, Pages 689-695

  Walker, Rowan ^a   Pussell, Bruce A ^b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Darbepoetin alpha; Epoetin alpha; Haemodialysis; Peritoneal dialysis; Pre dialysis

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HEMODIALYSIS; HEMODYNAMICS; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL;

AGED; ANEMIA; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS; RENAL DIALYSIS;

EID: 70349735840     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2009.01166.x     Document Type: Article

References (21)

1. Robinson BE. Epidemiology of chronic kidney disease and anemia. J. Am. Med. Dir. Assoc. 2006 7 : S3-6 quiz S17-21.
2. Obrador GT, Pereira BJ. Anaemia of chronic kidney disease: an under-recognized and under-treated problem. Nephrol. Dial. Transplant. 2002 17 : 44-6.
3. Eschbach JW, Abdulhadi MH, Browne JK et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann. Intern. Med. 1989 111 : 992-1000.
4. Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin. Nephrol. 2000 20 : 345-349.
5. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007 369 : 381-388.
6. Fishbane S. What is needed to achieve a hemoglobin of 11.0-13.0 g/dl in end-stage renal disease. Blood Purif. 2007 25 : 53-7.
7. Mcmahon L. Haemoglobin. Nephrology 2008 13 : S44- 56.
8. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005 68 : 1337-1343.
9. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin. J. Am. Soc. Nephrol. 2006 1 : 1205-1210.
10. Fishbane S, Berns JS. Evidence and implications of haemoglobin cycling in anaemia management. Nephrol. Dial. Transplant. 2007 22 : 2129-2132.
11. Gilbertson D, Ebben J, Foley R, Weinhandl E, Bradbury B, Collins A. Hemoglobin level variability: associations with mortality. Clin. J. Am. Soc. Nephrol. 2008 3 : 133-138.
12. Regidor DL, Kopple JD, Kovesdy CP et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J. Am. Soc. Nephrol. 2006 17 : 1181 1191.
13. Brockmoller J, Kochling J, Weber W, Looby M, Roots I, Neumayer HH. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Br. J. Clin. Pharmacol. 1992 34 : 499 508.
14. Ibbotson T, Goa KL. Darbepoetin alfa. Drugs 2001 61 : 2097 2104.
15. Pollock C, Mcmahon L. Biochemical and Hematological Targets Guidelines, 2005 Cited 12 June 2008.] Available from URL: http://www.cari.org.au/ Haemoglobin-rev-aug-2005.pdf
16. Kampf D, Eckardt KU, Fischer HC, Schmalisch C, Ehmer B, Schostak M. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations. Nephron 1992 61 : 393 398.
17. Yang W, Israni R, Brunelli S, Joffe M, Fishbane S, Feldman H. Hemoglobin variability and mortality in ESRD. J. Am. Soc. Nephrol. 2007 18 : 3164 3170.
18. Brunelli SM, Joffe MM, Israni RK et al. History-adjusted marginal structural analysis of the association between hemoglobin variability and mortality among chronic hemodialysis patients. Clin. J. Am. Soc. Nephrol. 2008 3 : 777 782.
19. Walker R, Pussell BA. Fluctuations in haemoglobin levels in haemodialysis patients receiving intravenous epoetin alfa or intravenous darbepoetin alfa. Nephrology (Carlton) 2007 12 : 448 451. (Pubitemid 47366636)
20. Nissenson AR, Swan SK, Lindberg JS et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am. J. Kidney Dis. 2002 40 : 110 118.
21. West RM, Harris K, Gilthorpe MS, Tolman C, Will EJ. Functional data analysis applied to a randomized controlled clinical trial in hemodialysis patients describes the variability of patient responses in the control of renal anemia. J. Am. Soc. Nephrol. 2007 18 : 2371 2376.